MTXRA: Efficacy, tolerability and preferences of per oral or subcutaneous methotrexate in patients with early rheumatoid arthritis

Rheumatoid arthritis, treatment and patient preferences

Treatment of early rheumatoid arthritis often requires long-term pharmacotherapy, where efficacy, side effects, and mode of administration all have a substantial impact on patients’ daily lives. In the national registry-based study MTXRA, the efficacy and tolerability of methotrexate administered orally versus subcutaneously are investigated; however, a crucial step has also been to make patients’ own treatment preferences visible.

The MTXRA preference study was developed as an integrated part of the main trial and offers patients with newly diagnosed rheumatoid arthritis the opportunity to express how they value different treatment-related factors, such as route of administration, side effects, and treatment burden. By systematically collecting these preferences, knowledge is generated that might otherwise be lacking in both clinical guidelines and medical decision-making processes. The study is led through close collaboration between academia and clinical practice by researchers with strong expertise in patient-oriented methodological development and rheumatology, including Karin Schölin Bywall, Anna Södergren, and Jennifer Viberg-Johansson.

What results are we expecting from the preference study?

The expected impact of the preference study is multifaceted. At the clinical level, the results may contribute to more individualized treatment decisions and strengthen shared decision-making between patients and healthcare professionals. When patients’ values are considered early in the treatment process, the conditions for improved adherence, reduced treatment discontinuation, and better perceived quality of life are enhanced. At the organizational level, the knowledge can be used in the development of care pathways and decision-support tools in which the patient perspective is more clearly integrated than previously.

At the scientific level, the MTXRA preference study contributes to methodological development in the field of patient preferences in rheumatology, an area where empirical knowledge remains limited. By linking preference data to an ongoing randomized registry-based clinical trial, unique opportunities are created to analyze the relationship between treatment, patient experience, and outcomes.

Overall, the MTXRA preference study contributes to more equitable, person-centered, and sustainable healthcare by giving patients a clearer voice in decisions that affect their long-term health. The study strengthens the connection between clinical research, patients’ experiences, and practical decision-making, thereby serving as a concrete example of how patient-centered research can generate value far beyond academia.